2
Clinical Trials associated with GC-310 / Not yet recruitingPhase 1/2IIT Multicenter, open, single-dose, dose escalation phase I/II clinical trial to evaluate the safety, tolerance and efficacy of GC310 adeno-associated virus injection in the treatment of Wilson disease patients
/ Not yet recruitingPhase 1/2 A Multicenter, Open-label, Single-dose, Dose-escalation Phase I/II Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GC310 Adeno-associated Virus Injection in the Treatment of Patients With Wilson's Disease (WD)
The goal of this clinical trial is to learn if GC310 (AAV5-ATP7B) gene therapy can treat Wilson's Disease (WD) in patients over the age of 18 years old. The main questions it aims to answer are:
Is GC310 safe and tolerable to WD patients? What is the recommended phase II dose (RP2D)? What is the change from baseline in 24-hour urinary copper concentration after 52 weeks of administration?
Participants will be administrated GC310 intravenously and be followed up for 52 weeks to observe drug safety, tolerability and efficacy .
100 Clinical Results associated with GC-310
100 Translational Medicine associated with GC-310
100 Patents (Medical) associated with GC-310
100 Deals associated with GC-310